Evidence map›Paper›PMID 38315829›Full record

ArticleUrology practice2024

Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience.

Wesley Yip, Melissa J Assel, Nathan C Wong, Andrew T Tracey, Ricardo G Alvim, Lucas Nogueira, Nima Almassi, Nirmish Singla, Timothy N Clinton, Daniel D Sjoberg and 9 more

Open access · greenAbstract read
In one paragraph

Article in Urology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

Wesley YipUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Melissa J AsselDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Nathan C WongUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew T TraceyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ricardo G AlvimUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Lucas NogueiraUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Nima AlmassiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Nirmish SinglaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Timothy N ClintonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniel D SjobergDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Eugene J PietzakUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Eugene K ChaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Timothy F DonahueUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Guido DalbagniUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Bernard H BochnerUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Dean F BajorinGenitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USSpanish Oncology Genitourinary Group · ES

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

introductionWe evaluated surgical trends, perioperative management evolution, and oncologic outcomes in patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) at a tertiary cancer center over a 24-year period.

methodsBetween 1995 and 2018, we evaluated 743 consecutive patients with UTUC who underwent RNU. Generalized additive models were used to estimate the associations between date of surgery and continuous outcomes using a linear model, dichotomous outcomes using a logit link, categorical outcomes using multinomial models, and 2- and 5-year survival outcomes using Cox proportional hazards models.

resultsOver the study period, preoperative diagnostic endoscopic biopsies increased from 10% to 66%, along with the proportion of patients who underwent RNU for high-grade disease from 55% to 91%. The rate of open RNU declined from 100% to 56% with a rise in minimally invasive approaches. Median lymph node yield increased with more retroperitoneal lymph node dissections performed. Neoadjuvant chemotherapy utilization increased with a contemporary utilization rate of 32%, coinciding with an increase in pT0 rate from 2% to 8%. Cancer-specific survival probabilities improved over the study period, while metastasis-free and overall survival remained stable.

conclusionsWe found several changes in treatment patterns and outcomes for patients with UTUC over the past 2 decades. How individual alterations in management factors, such as patient selection, perioperative chemotherapy, lymphadenectomy, and salvage therapies, impact patient outcomes is challenging in the setting of multiple overlapping practice changes for this rare disease and warrants further investigation.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsHumansLymph Node ExcisionNephroureterectomyneoadjuvant chemotherapyoutcomessurgeryupper tract urothelial carcinomaurothelial carcinoma

Identifiers

PMID38315829
PMCPMC11323897
OpenAlexW4391527590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.